Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596601 | 0.86 | HPGD (0.36) | IRAK4HDAC1HDAC6HDAC8BAZ2B | |
| SCHEMBL18407331 | 0.84 | IRAK4 (0.39) | IRAK4HDAC1HDAC6HDAC8CNR1 | |
| SCHEMBL22618722 | 0.81 | NPC1 (0.40) | IRAK4HDAC1HDAC6HDAC8HPGD | |
| SCHEMBL12894573 | 0.81 | PARP1 (0.34) | IRAK4HDAC1HDAC6HDAC8BAZ2B | |
| SCHEMBL23193123 | 0.80 | IRAK4 (0.38) | IRAK4HDAC1HDAC6HDAC8CNR1 | |
| SCHEMBL20464221 | 0.80 | HDAC6 (0.39) | IRAK4HDAC1HDAC6HDAC8HPGD | |
| SCHEMBL8965333 | 0.79 | KDM4E (0.35) | IRAK4HDAC1HDAC6HDAC8 | |
| SCHEMBL17281398 | 0.79 | DAGLA (0.36) | IRAK4 | |
| SCHEMBL20462599 | 0.79 | NPC1 (0.43) | IRAK4HPGDNPC1POLBRAB9A | |
| SCHEMBL77505 | 0.79 | DAGLA (0.40) | IRAK4HDAC1HDAC6HDAC8NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | IRAK4 4064/4885HDAC1 42/4885HDAC6 16/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | IRAK4 4064/4885HDAC1 42/4885HDAC6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.